Meeting
2017 Gastrointestinal Cancers Symposium
Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).
Authors
Austin G. Duffy
National Cancer Institute at the National Institutes of Health, Bethesda, MD
Austin G. Duffy , Drew Pratt , David E Kleiner , Donna Mabry , Suzanne Fioravanti , Melissa Walker , William Douglas Figg , Seth M. Steinberg , Victoria Anderson , Venkatesh Krishnasamy , Bradford J. Wood , Tim F. Greten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01853618
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 316)
DOI
10.1200/JCO.2017.35.4_suppl.316
Abstract #
316
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2016 ASCO Annual Meeting
Tremelimumab: A monoclonal antibody against CTLA-4—in combination with subtotal ablation (trans catheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2016 Gastrointestinal Cancers Symposium
![Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).](https://d201v5jt9ylckg.cloudfront.net/173/11384/120467/120467_poster_pv.jpg)
Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC).
First Author: Austin G. Duffy
Poster
2015 ASCO Annual Meeting
A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).
First Author: Austin G. Duffy